Acute HIV revisited: new opportunities for treatment and prevention.

PubWeight™: 2.30‹?› | Rank: Top 2%

🔗 View Article (PMC 379335)

Published in J Clin Invest on April 01, 2004


Christopher D Pilcher1, Joseph J Eron, Shannon Galvin, Cynthia Gay, Myron S Cohen

Author Affiliations

1: Department of Medicine, University of North Carolina at Chapel Hill, 27599-7215, USA.

Associated clinical trials:

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV | NCT00090779

A Phase I/II Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 | NCT02042248

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy (HXTC) | NCT02208167

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI 05) | NCT02384395

Acute HIV Infection Observational Study | NCT00296660

Long-term Follow-up of HIV Infected Patients Identified During Early Infection | NCT00086372

Articles citing this

Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54

Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72

The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12

Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.89

Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89

PCR-based pooling of dried blood spots for detection of malaria parasites: optimization and application to a cohort of Ugandan children. J Clin Microbiol (2010) 1.77

Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. Bull World Health Organ (2009) 1.76

Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46

Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41

The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS (2009) 1.37

Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr (2013) 1.31

Identification of primary HIV-1C infection in Botswana. AIDS Care (2008) 1.29

Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. Clin Infect Dis (2011) 1.28

Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. AIDS Behav (2009) 1.26

Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav (2009) 1.26

Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med (2011) 1.19

Three-dimensional array-based group testing algorithms. Biometrics (2008) 1.18

Targeted testing for acute HIV infection in North Carolina. AIDS (2009) 1.14

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS (2008) 1.05

Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? J Acquir Immune Defic Syndr (2014) 1.03

Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03

Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, Brazil. PLoS One (2011) 1.02

Prevalence of seroconversion symptoms and relationship to set-point viral load: findings from a subtype C epidemic, 1995-2009. AIDS (2012) 1.00

When does overuse of antibiotics become a tragedy of the commons? PLoS One (2012) 0.99

Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS (2013) 0.98

The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301). PLoS One (2012) 0.95

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One (2013) 0.92

Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection. J Virol (2011) 0.92

Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90

The use of Nanotrap particles technology in capturing HIV-1 virions and viral proteins from infected cells. PLoS One (2014) 0.89

A Qualitative Study of Providers' Perception of Adherence of Women Living with HIV/AIDS in Puerto Rico. Qual Rep (2010) 0.88

Rectal microbicide development. Curr Top Microbiol Immunol (2014) 0.87

HPTN 062: a feasibility and acceptability pilot intervention to reduce HIV transmission risk behaviors among individuals with acute and early HIV infection in Lilongwe, Malawi. AIDS Behav (2014) 0.86

Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. J Clin Immunol (2005) 0.84

The HIV treatment cascade in acutely infected people: informing global guidelines. Curr Opin HIV AIDS (2015) 0.81

The potential role of biomarkers in HIV preventive vaccine trials. J Acquir Immune Defic Syndr (2009) 0.81

Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. PLoS One (2016) 0.81

HIV transmissions by stage in dynamic sexual partnerships. J Theor Biol (2012) 0.80

Emerging infectious diseases. J Clin Invest (2004) 0.80

Coma as a presenting symptom of primary HIV infection. Sex Transm Infect (2007) 0.79

A stochastic multi-scale model of HIV-1 transmission for decision-making: application to a MSM population. PLoS One (2013) 0.79

HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. Lab Invest (2014) 0.78

Amplified transmission of HIV-1: missing link in the HIV pandemic. Trans Am Clin Climatol Assoc (2006) 0.77

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. PLoS One (2016) 0.77

Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters. PLoS One (2014) 0.75

Differences in Risk Behavior and Demographic Factors between Men who have Sex with Men with Acute and Non-Acute Human Immunodeficiency Virus Infection in a Community-Based Testing Program in Los Angeles. J Acquir Immune Defic Syndr (2016) 0.75

Acute infections, cost and time to reporting of HIV test results in three U.S. State Public Health Laboratories. J Infect (2016) 0.75

A severe manifestation of primary HIV-1 infection in an adolescent. BMJ Case Rep (2014) 0.75

Diversity of trends of viremia and T-cell markers in experimental acute feline immunodeficiency virus infection. PLoS One (2013) 0.75

A cross-sectional study on the relationship of age, gestational age and HIV infection to bacterial vaginosis and genital mycoplasma infection. BMJ Open (2015) 0.75

Articles cited by this

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18

Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect (1999) 17.95

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43

Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87

Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68

Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66

Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet (1989) 11.39

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32

HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77

Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73

Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 7.68

Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07

The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04

Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57

Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26

Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04

Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS (1998) 5.64

Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35

Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS (2000) 5.14

Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98

Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr (1994) 4.81

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76

A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis (2001) 4.73

Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80

The geography of gonorrhea. Empirical demonstration of core group transmission. Am J Epidemiol (1983) 3.76

The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med (2003) 3.48

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48

Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16

Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol (1998) 3.08

Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol (2000) 2.97

Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94

Using social network and ethnographic tools to evaluate syphilis transmission. Sex Transm Dis (1998) 2.81

Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med (2003) 2.79

Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 2.54

Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51

Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42

Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS (2000) 2.37

Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33

Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 2.25

Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12

Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08

HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08

Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07

Risk factors and clinical presentation of acute primary HIV infection in India. JAMA (1997) 2.02

Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med (2003) 1.96

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91

The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS (1999) 1.76

Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest (2001) 1.72

Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.55

Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis (1993) 1.52

Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis (2000) 1.51

Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS (1994) 1.38

Sexual transmission during the incubation period of primary HIV infection. JAMA (2001) 1.37

Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32

Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis (2003) 1.31

The role of the oral environment in HIV-1 transmission. J Am Dent Assoc (1998) 1.24

Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med (2001) 1.24

Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol (2002) 1.24

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis (1999) 1.21

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med (2000) 1.20

Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.20

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol (2003) 1.19

Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2. J Clin Microbiol (1998) 1.05

Acute HIV infection among patients tested for mononucleosis. N Engl J Med (1999) 1.04

A cluster of HIV infection among heterosexual people without apparent risk factors. N Engl J Med (1989) 1.04

Endogenous salivary inhibitors of human immunodeficiency virus. Arch Oral Biol (1999) 0.98

Pig-tailed macaques infected with human immunodeficiency virus (HIV) type 2GB122 or simian/HIV89.6p express virus in semen during primary infection: new model for genital tract shedding and transmission. J Infect Dis (2001) 0.96

Partner counseling and referral services to identify persons with undiagnosed HIV--North Carolina, 2001. MMWR Morb Mortal Wkly Rep (2003) 0.94

Unsuspected primary human immunodeficiency virus type 1 infection in seronegative emergency department patients. J Infect Dis (1994) 0.91

Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis (2003) 0.91

Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J Gen Virol (1998) 0.90

HIV-1 shedding and chlamydial urethritis. JAMA (1996) 0.87

Shedding of HIV-1 in semen during primary infection. AIDS (1997) 0.84

Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV Med (2001) 0.83

Urban clusters of sexually transmitted diseases in the city of Seville, Spain. Sex Transm Dis (1985) 0.82

Articles by these authors

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87

Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79

Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (2009) 5.72

Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66

Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40

Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89

HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88

AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Surplus men, sex work, and the spread of HIV in China. AIDS (2005) 3.64

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med (2003) 3.32

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24

Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis (2006) 3.17

Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96

Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94

Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr (2011) 2.49

Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44

Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43

The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis (2005) 2.31

Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis (2006) 2.31

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27

Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25

China's syphilis epidemic: a systematic review of seroprevalence studies. Sex Transm Dis (2006) 2.23

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22

Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis (2011) 2.20

Prevalence of HIV infection among young adults in the United States: results from the Add Health study. Am J Public Health (2006) 2.17

Moving forward in HIV-associated cancer. J Clin Oncol (2014) 2.14

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14

Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis (2010) 2.13

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05

Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.02

Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr (2006) 2.01

Keep them in school: the importance of education as a protective factor against HIV infection among young South African women. Int J Epidemiol (2008) 2.00

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96

Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med (2003) 1.96

Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis (2005) 1.95

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91

Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87

HIV incidence among men who have sex with men in China: a meta-analysis of published studies. PLoS One (2011) 1.79

Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77

Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77

Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care (2006) 1.76

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74

Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73

Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis (2011) 1.70

Splines for trend analysis and continuous confounder control. Epidemiology (2011) 1.69

Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68

Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol (2009) 1.63

HIV treatment as prevention: to be or not to be? J Acquir Immune Defic Syndr (2010) 1.59

Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr (2002) 1.59

Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women. J Clin Microbiol (2002) 1.58

Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses (2010) 1.58

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57

CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol (2012) 1.57

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis (2013) 1.55

Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55

HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55

"No one's at home and they won't pick up the phone": using the Internet and text messaging to enhance partner services in North Carolina. Sex Transm Dis (2014) 1.55

The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55